These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11912950)

  • 1. Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure.
    Shiga T; Matsuda N; Fuda Y; Haruta S; Hagiwara N; Kasanuki H
    J Cardiol; 2002 Mar; 39(3):159-64. PubMed ID: 11912950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.
    Morita N; Tanaka K; Yodogawa K; Hayashi M; Akutsu K; Yamamoto T; Satoh N; Kobayashi Y; Katoh T; Takano T
    Pacing Clin Electrophysiol; 2007 Oct; 30(10):1242-53. PubMed ID: 17897127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment for perioperative arrhythmias with nifekalant hydrochloride].
    Nishida M; Okada H; Murakami M; Hamano K
    Kyobu Geka; 2006 Mar; 59(3):210-3. PubMed ID: 16528993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of Nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: a study of patients with out-of-hospital cardiac arrest].
    Amino M; Yoshioka K; Iwata O; Fujikura H; Deguchi Y; Ban K; Shiina Y; Goto S; Handa S; Tanabe T; Nakagawa Y; Morita S; Iwase H; Yamamoto I; Inokuchi S; Marutani Y
    J Cardiol; 2003 Mar; 41(3):127-34. PubMed ID: 12674997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
    Chiladakis JA; Kalogeropoulos A; Patsouras N; Manolis AS
    J Am Coll Cardiol; 2004 Aug; 44(4):859-63. PubMed ID: 15312872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficiency of nifekalant hydrochloride for the prevention of ventricular tachycardia during cardiac surgery].
    Sakaguchi M; Takemura T; Shimamura Y; Tsuda Y; Iwasa S
    Kyobu Geka; 2004 Mar; 57(3):191-5. PubMed ID: 15035072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of life-threatening ventricular tachyarrhythmia by a novel and pure class-III agent, nifekalant hydrochloride.
    Ohashi J; Yasuda S; Miyazaki S; Shimizu W; Morii I; Kurita T; Kawamura A; Kamakura S; Nonogi H
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):274-9. PubMed ID: 17204905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergency department use of intravenous procainamide for patients with acute atrial fibrillation or flutter.
    Stiell IG; Clement CM; Symington C; Perry JJ; Vaillancourt C; Wells GA
    Acad Emerg Med; 2007 Dec; 14(12):1158-64. PubMed ID: 18045891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing electrical cardioversion and preventing immediate reinitiation of hemodynamically deleterious atrial fibrillation with class III drug pretreatment.
    Hayashi M; Tanaka K; Kato T; Morita N; Sato N; Yasutake M; Kobayashi Y; Takano T
    J Cardiovasc Electrophysiol; 2005 Jul; 16(7):740-7. PubMed ID: 16050832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study.
    Chrysostomou C; Beerman L; Shiderly D; Berry D; Morell VO; Munoz R
    Anesth Analg; 2008 Nov; 107(5):1514-22. PubMed ID: 18931208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
    Hongo RH; Themistoclakis S; Raviele A; Bonso A; Rossillo A; Glatter KA; Yang Y; Scheinman MM
    J Am Coll Cardiol; 2004 Aug; 44(4):864-8. PubMed ID: 15312873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reduction of auricular fibrillation and tachycardia using intravenous flecainide].
    Cohen-Solal A; Juliard JM; Jaeger P; Farinotti P; Dahan M; Charlier P; Boujon B; Aumont MC
    Arch Mal Coeur Vaiss; 1987 Jul; 80(8):1290-6. PubMed ID: 3120666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of IKr blocker nifekalant on atrial action potential duration after successful internal cardioversion of chronic atrial fibrillation.
    Kofune T; Watanabe I; Okubo K; Okumura Y; Masaki R; Shindo A; Saito S
    Pacing Clin Electrophysiol; 2005 May; 28(5):391-6. PubMed ID: 15869670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.
    Kafkas NV; Patsilinakos SP; Mertzanos GA; Papageorgiou KI; Chaveles JI; Dagadaki OK; Kelesidis KM
    Int J Cardiol; 2007 Jun; 118(3):321-5. PubMed ID: 17049640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of nifekalant on acute electrical remodelling in rapid atrial pacing canine model.
    Tang M; Zhang S; Sun Q; Hua W; Huang CX
    Chin Med J (Engl); 2006 Dec; 119(24):2056-61. PubMed ID: 17199956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intravenous nifekalant, a class III antiarrhythmic drug, on atrial vulnerability parameters in patients with paroxysmal atrial fibrillation.
    Minami T; Isomoto S; Nakao K; Komiya N; Fukae S; Centurion OA; Yano K
    Pacing Clin Electrophysiol; 2004 Feb; 27(2):212-7. PubMed ID: 14764172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.
    Hennersdorf MG; Perings SM; Zühlke C; Heidland UE; Perings C; Heintzen MP; Strauer BE
    Intensive Care Med; 2002 Jul; 28(7):925-9. PubMed ID: 12122531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
    Naegeli B; Straumann E; Bertel O
    Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reverse use-dependent QT prolongation during infusion of nifekalant in a case of recurrent ventricular tachycardia with old myocardial infarction.
    Shiga T; Ando S; Suzuki T; Matsuda N; Kasanuki H
    J Electrocardiol; 2001 Jan; 34(1):77-80. PubMed ID: 11239376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of transient atrial rhythm occurring between typical atrial flutter and its termination with class III drugs.
    Morita N; Kobayashi Y; Iwasaki YK; Hayashi M; Miyauchi Y; Atarashi H; Tanaka K; Katoh T; Mizuno K
    Pacing Clin Electrophysiol; 2008 Aug; 31(8):943-54. PubMed ID: 18684249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.